MARLBOROUGH, Mass., May 5, 2014 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the treatment of atrial fibrillation (AF), today announced that recent data will be presented at two major conferences focusing on cardiac rhythm management, the 2014 Stanford Biodesign New Arrhythmia Technologies Retreat, being held May 6th in Stanford, CA., and 2014 Heart Rhythm Society (HRS) Scientific Sessions, being held May 7-10 in San Francisco, CA.
At the Stanford Biodesign forum, Vivek Reddy, MD, of Mt. Sinai Hospital and a principal investigator of CardioFocus' Pivotal Trial of the HeartLight® Endoscopic Ablation System, will discuss Laser Ablation of Atrial Fibrillation during a session entitled "Advances in Mapping and Ablation (Part II)." The session will be moderated by Andrea Natale, MD, Texas Cardiac Arrhythmia Research Foundation, also a principal investigator of the same trial. The HeartLight U.S. Pivotal trial, now midway through the 12-month follow-up phase, is scheduled to conclude before year end 2014. In addition, Stephen Sagon, President of CardioFocus, will be speaking during the Stanford Biodesign meeting about European results from the regular clinical use of the HeartLight System.
At the HRS Scientific Sessions, several oral and poster presentations will also be on the program. Presentation authors will lead discussions featuring compelling clinical evidence regarding laser ablation, a unique technique to achieve durable pulmonary vein isolation. The HRS presentation details are as follows:
- "Laser Ablation of the PVs: Techniques and Outcomes"
Authors: Josef Kautzner, MD, PhD. Institute for Clinical and Experimental Medicine, Prague, Czech Republic
Session: AF04 - New and Old Technologies for AF Ablation
Date / Time: May 7, 2014 at 3:00 3:15 p.m. PT
Location: Room 3001, Moscone West
- "Laser, Ultrasound Cryo Ablation, and Noninvasive Ablation"
Authors: Paul J. Wang, MD, FHRS, CCDS. Stanford University School of Medicine, Stanford, CA
Session: 020 - New Arrhythmia Technologies
Date / Time: May 8, 2014 at 8:45 9:00 a.m. PT
Location: Room 2014, Moscone West
- "The Laser Balloon"
Authors: Boris Schmidt, MD, FHRS. Cardioangiologisches Centrum Bethanien, Frankfurt/Main, Germany
Session: 031 - Novel Technology to Treat AF
Date / Time: May 8, 2014 at 10:55 11:15 a.m. PT
Location: Room 2007, Moscone West
- PO01 - Featured Poster Session and Reception
Date / Time: May 7, 2014 at 6:00 7:30 p.m. PT
- Location: Poster Town, Exhibit Hall
- "Pulmonary vein orientation has a strong impact on medium-term atrial fibrillation free survival in patients undergoing endoscopic laser balloon ablation"
Authors: Pim Gal, MD, et al.
- "Pulmonary Vein Isolation Using a Visually-Guided Laser Balloon Catheter: Results of the US Feasibility Study"
Authors: Srinivas Dukkipati, MD, et al.
- PO02 - Poster Session II
Date / Time: May 8, 2014 at 9:30 a.m. 12:00 p.m. PT
Location: Poster Town, Exhibit Hall
- "Anatomical predictors for successful pulmonary vein isolation using balloon-based ablation technologies"
Authors: Alexey Tsyganov, MD, et al.
Stephen Sagon, President of CardioFocus, said, "We are very much looking forward to the Stanford Biodesign and Heart Rhythm meetings as they offer invaluable opportunities to discuss emerging technology with both researchers and practitioners. With more than 2,000 patients now treated in Europe using the HeartLight system, we are especially excited to hear from the many renowned cardiologists on the program detailing cardiac advancements involving laser ablation and the HeartLight System."
About CardioFocus, Inc.
CardioFocus, Inc. is a medical device manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF). Its novel HeartLight® Endoscopic Ablation System for catheter ablation incorporates an endoscope to provide physicians with the capacity to see within the heart, and for the first time, visually direct the application of laser energy to achieve durable pulmonary vein isolation.
The HeartLight Endoscopic Ablation System is commercially available at leading institutions throughout Europe and in Australia. The device is investigational in the U.S., and currently the focus of a pivotal trial due to conclude in 2014. CardioFocus is headquartered in Marlborough, MA, USA. For more information on the company and its technology, please visit www.CardioFocus.com.
The scientific information discussed in this news release is preliminary and investigative. The CardioFocus HeartLight Endoscopic Ablation System is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the system. Only FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Healthcare professionals should refer to/rely upon FDA-approved labeling for the products, and not the information discussed in this news release.
SOURCE CardioFocus, Inc.